Loading...
Kairos Pharma, Ltd.
KAPA•AMEX
Healthcare
Biotechnology
$0.57
$0.03(5.92%)
Kairos Pharma, Ltd. (KAPA) Company Profile & Overview
Explore Kairos Pharma, Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Kairos Pharma, Ltd. (KAPA) Company Profile & Overview
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
SectorHealthcare
IndustryBiotechnology
CEODr. John S. Yu M.D., Ph.D.
Contact Information
Company Facts
1 Employees
IPO DateSep 16, 2024
CountryUS
Actively Trading